

**Remarks**

No new matter has been added. Applicants again request entry of the amendments as set forth herein.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Allen C. Turner', with a long, sweeping horizontal line extending to the right.

Allen C. Turner  
Registration No. 33,041  
Attorney for Applicants  
TRASKBRITT, PC  
P. O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: (801) 532-1922

Date: October 30, 2001

VERSION SHOWING CHANGES MADE

[ [0056] FIGS. 20A-20F recite the nucleotide sequence of pICL 5620BPS (circular).]

[0162] The *tet* gene of plasmid pMLP10 has been inactivated by deletion of the BamHI-SalI fragment, to generate pMLP10 $\Delta$ SB. Using primer set PCR/MLP1 (SEQ ID NO: 14) and PCR/MLP3 (SEQ ID NO: 16) a 210 bp fragment containing the Ad5-ITR, flanked by a synthetic SalI restriction site was amplified using pMLP10 DNA as the template. The PCR product was digested with the enzymes EcoRI and SgrAI to generate a 196 bp. fragment. Plasmid pMLP10 $\Delta$ SB was digested with EcoRI and SgrAI to remove the ITR. This fragment was replaced by the EcoRI-SgrAI-treated PCR fragment to generate pMLP/SAL. Plasmid pCMV-Luc was digested with PvuII to completion and recirculated to remove the SV4O-derived poly-adenylation signal and Ad5 sequences with exception of the Ad5 left-terminus. In the resulting plasmid, pCMV-luc $\Delta$ Ad, the Ad5 ITR was replaced by the Sal-site-flanked ITR from plasmid pMLP/SAL by exchanging the XmnI-SacII fragments. The resulting plasmid, pCMV-luc $\Delta$ Ad/SAL, the Ad5 left terminus and the CMV-driven luciferase gene were isolated as an SalI-SmaI fragment and inserted in the SalI and HpaI digested plasmid pBLCATS, to form plasmid pICL. Plasmid pICL is represented in FIG. 19; its sequence is presented in [FIGS. 20A -20F] the sequence listing (SEQ ID NO: 21).